ArticleOncotarget2017
Detection of
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Liquid biopsy: a new window on the BRCA genes.ESMO open · 2026Review
- Biodistribution and dosimetry of the carbon-11 labelled PARP1-selective PET radiopharmaceutical [EJNMMI research · 2026Article
- Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer.Cancer medicine · 2026Review
- The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review).Diagnostics (Basel, Switzerland) · 2025Review
- The role of circulating tumor DNA in gynecological cancer management.Frontiers in oncology · 2025Review
- Circulating tumor cells: indicators of cancer progression, plasticity and utility for therapies.Pathology oncology research : POR · 2025Review
- Review
- The Role of Circulating Tumor DNA in Ovarian Cancer.Cancers · 2024Review
- Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications.British journal of cancer · 2024Review
- Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.Frontiers in oncology · 2024Review
- Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.Frontiers in oncology · 2023Review
- Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Potential clinical utility of liquid biopsies in ovarian cancer.Molecular cancer · 2022Review
- Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?International journal of oncology · 2022Article
- Somatic DNA Damage Response and Homologous Repair Gene Alterations and Its Association With Tumor Variant Burden in Breast Cancer Patients With Occupational Exposure to Pesticides.Frontiers in oncology · 2022Article
- Review
- Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.Cancers · 2021Review
- Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?Journal of oncology · 2021Review
- Prediction of the treatment response in ovarian cancer: a ctDNA approach.Journal of ovarian research · 2020Review
- Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery.BioResearch open access · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 25% of patients with ovarian cancer harbor a pathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.